Uveal melanoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]

Overview

Pharmacologic medical therapy is recommended among patients with metastatic disease and include chemotherapy, immunotherapy, and targeted therapy.

Pharmacologic medical therapy is recommended among patients with metastatic disease:^[1]^[2]

Chemotherapy
Immunotherapy
- Checkpoint blockade
  - Pembrolizumab
  - Ipilimumab + nivolumab
  - Ipilimumab + nivolumab
  - Ipilimumab + radioembolization
  - Ipilimumab + nivolumab +radioembolization
- TILs (tumor-infiltrating lymphocytes)
- T cell redirection
- Antibody–drug conjugate
  - Glembatumumab vedotin
Targeted therapy
- PKC (protein kinase C)/ MEK
  - AEB071 + BYL719
  - Intermittent selumetinib
  - Selumetinib +/– paclitaxel
  - Binimetinib + AEB071
- Multi-kinase inhibition
  - Sorafenib (STREAM)
  - Cabozantinib versus temozolomide/ dacarbazine
- Epigenetic therapy
  - HDAC (histone deacetylase) inhibition
    - Vorinostat
    - Pembrolizumab + entinostat (PEMDAC)
  - BET (bromodomain and extra-terminal motif) inhibition
- Liver-directed therapy
  - IHP (isolated hepatic perfusion)
  - PHP (percutaneous isolated hepatic perfusion) with melphalan

↑ Yang J, Manson DK, Marr BP, Carvajal RD (2018). “Treatment of uveal melanoma: where are we now?”. Ther Adv Med Oncol. 10: 1758834018757175. doi:10.1177/1758834018757175. PMC 5824910. PMID 29497459.
↑ Shoushtari AN, Carvajal RD (2016). “Treatment of Uveal Melanoma”. Cancer Treat. Res. 167: 281–93. doi:10.1007/978-3-319-22539-5_12. PMID 26601868.